Synthetic Lethal and Resistance Interactions with BET Bromodomain Inhibitors in Triple-Negative Breast Cancer
Shaokun Shu, Hua‐Jun Wu, Jennifer Y. Ge, Rhamy Zeid, Isaac S. Harris, Bojana Jovanović, Katherine C. Murphy, Binbin Wang, Xintao Qiu, Jennifer E. Endress, Jaime M. Reyes, Klothilda Lim, Alba Font‐Tello, Sudeepa Syamala, Tengfei Xiao, Chandra Sekhar Reddy Chilamakuri, Evangelia K. Papachristou, Clive S. D’Santos, Jayati Anand, Kunihiko Hinohara, Wei Li, Thomas O. McDonald, Adrienne Luoma, Rebecca Modiste, Quang‐Dé Nguyen, Brittany C. Michel, Paloma Cejas, Cigall Kadoch, Jacob D. Jaffe, Kai W. Wucherpfennig, Jun Qi, X. Shirley Liu, Henry W. Long, Myles Brown, Jason S. Carroll, Joan S. Brugge, James E. Bradner, Franziska Michor, Kornélia Polyák
Topics & Concepts
BromodomainBiologyBRD4Triple-negative breast cancerCRISPRBET inhibitorCancer researchSynthetic lethalityComputational biologyBreast cancerChromatinGeneticsCancerGeneEpigeneticsDNA repairProtein Degradation and InhibitorsCAR-T cell therapy researchMultiple Myeloma Research and Treatments